当前位置: 首页 > 期刊 > 《中国美容医学》 > 20203
编号:13509456
黄褐斑发病机制及诊疗研究进展(6)
http://www.100md.com 2020年2月1日 《中国美容医学》 20203
     [33]Nofal A,Ibrahim ASM,Nofal E,et al.Topical silymarin versus hydroquinone in the treatment of melasma:A comparative study[J].J Cosmet Dermatol,2019,18(1):263-270.

    [34]Lyons A,Stoll J,Moy R.A randomized, double-blind, placebo-controlled, split-face study of the efficacy of topical epidermal growth factor for the treatment of melasma[J].J Drugs Dermatol,2018,17(9):970-973.

    [35]Del Rosario E,Florez-Pollack S,Zapata L,et al.Randomized,placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma[J].J Am Acad Dermatol,2018,78(2):363-369.

    [36]Janney MS,Subramaniyan R,Dabas R,et al.A randomized controlled study comparing the efficacy of topical 5% tranexamic acid solution versus 3% hydroquinone cream in melasma[J].J Cutan Aesthet Surg,2019,12(1):63-67.

    [37]張金娥,景焕,卫静宜,等.5%氨甲环酸透皮给药治疗黄褐斑疗效分析[J].中国美容医学,2019,28(5):11-15.

    [38]Cohen PR.Melasma treatment: A novel approach using a topical agent that contains an anti-estrogen and a vascular endothelial growth factor inhibitor[J]. Med Hypotheses,2017,101:1-5.

    [收稿日期]2019-11-10

    本文引用格式:彭鹰,刘毅.黄褐斑发病机制及诊疗研究进展[J].中国美容医学,2020,29(3):162-166., http://www.100md.com(彭鹰 刘毅)
上一页1 2 3 4 5 6